Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

737 results about "Natural killer cell" patented technology

Natural killer cells, or NK cells, are a type of cytotoxic lymphocyte critical to the innate immune system. The role NK cells play is analogous to that of cytotoxic T cells in the vertebrate adaptive immune response. NK cells provide rapid responses to virus-infected cells, acting at around 3 days after infection, and respond to tumor formation. Typically, immune cells detect the major histocompatibility complex (MHC) presented on infected cell surfaces, triggering cytokine release, causing lysis or apoptosis. NK cells are unique, however, as they have the ability to recognize stressed cells in the absence of antibodies and MHC, allowing for a much faster immune reaction. They were named "natural killers" because of the initial notion that they do not require activation to kill cells that are missing "self" markers of MHC class 1. This role is especially important because harmful cells that are missing MHC I markers cannot be detected and destroyed by other immune cells, such as T lymphocyte cells.

CD19 and CD22 chimeric antigen receptors and uses thereof

The present disclosure provides compositions and methods for treating diseases associated with expression of CD19 and / or CD22, e.g., by administering a recombinant T cell or natural killer (NK) cell comprising a CD22 CAR and a CD19 CAR as described herein. The disclosure also relates to CAR molecules specific to CD22 and / or CD19, methods of making a cell comprising the same and vectors encoding the same.
Owner:NOVARTIS AG

Stealth lipid nanoparticle compositions for cell targeting

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., immune effector cells such as T cells, B cells, natural killer cells, and dendritic cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Owner:GENERATION BIO CO

Method for evaluating specific killing ability of engineered natural killer cells

The invention relates to a method for evaluating the specific killing ability of engineered natural killer cells. Specifically, the invention provides a method for dynamically detecting the killing ability of the immune effector cell in real time, a target cell capable of stably expressing fluorescent protein is constructed, and the real-time killing of the immune effector cell on the target cell is accurately reflected through the disappearance condition of a fluorescence signal of the target cell. In the system provided by the invention, target cells can be added again for continuous challenge, tumor invasion is simulated, and the in-vitro killing function of the natural killer cells of the chimeric antigen receptor is comprehensively evaluated. The method provided by the invention provides effective and accurate evaluation for process development of immune effector cells, especially engineered and modified NK cell products, and provides effective analysis support for researching immune curative effects of NK cells and the like.
Owner:NEUKIO BIOTHERAPEUTICS (SHANGHAI) CO LTD

CD83-binding chimeric antigen receptors

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Isolation and expansion of natural killer cells using fluorescence-activated droplet sorting

PCT designated stage expiredWO2025050133A1Flow mixersTransportation and packagingNatural Killer Cell Inhibitory ReceptorsCellular Expansion
A high-throughput microfluidics-based fluorescence activated droplet sorting (FADS) system provides activation, sorting, and feeder cell-free expansion of NK cells that are enriched for killing activity. The NK cells are activated and identified based on their ability to kill target cells, such as tumor cells, without prior sensitization. The diversity of endogenous NK cells can be overcome to allow selection of a highly effective population of cells for therapeutic use, such as in the treatment of cancer.
Owner:NORTHEASTERN UNIV (US)

Method for efficiently infecting human natural killer cells and other immune cells with pseudovirus

The present disclosure belongs to the field of biotechnology, and specifically relates to a method for efficiently infecting human natural killer (NK) cells and other immune cells with a pseudovirus. Specifically, a viral transfection system provided in the present disclosure has an envelope plasmid with a protein having an X—Y—Z structure. The X is an extracellular (ex) structure of a gibbon ape leukemia virus (GALV) envelope glycoprotein, the Y is a transmembrane (TM) structure of the GALV envelope glycoprotein, and the Z is an intracellular segment portion of a murine virus gene.
Owner:BEIJING GENE MINK BIOTECHNOLOGY CO LTD

Humanized immunodeficient mouse model

PendingCN120051204ACompounds screening/testingUnknown materialsImmunodeficient mouse modelHuman cell
In some aspects, the disclosure provides humanized immunodeficient mouse models that support long term transplantation and function of human T cells, natural killer cells, and bone marrow cells without the need for conditioning.
Owner:JACKSON LAB THE +1

Engineered natural killer cells with enhanced tumor killing performance

The invention relates to an engineered natural killer cell, in particular to a natural killer cell with enhanced tumor killing performance, a polynucleotide for coding CAR19 and a polynucleotide for coding IL-24 are integrated in a genome of the natural killer cell, and the engineered natural killer cell simultaneously expresses CAR19 and IL-24.
Owner:SHANGHAI PINPOINT MEDICAL TECH CO LTD

Devices and methods for modulating immune system activity in a cancer patient and treating cancer

Described herein are methods and devices for monitoring or modulating an immune system in a subject with cancer, and methods and devices for treating a cancer in a subject. The implanted device can electrically stimulate the splenic nerve of the subject, which can modulate the inflammatory system (for example, by increasing or decreasing the blood level of one or more pro-inflammatory cytokines and / or anti-inflammatory cytokines to increase or decrease inflammation in the subject) and / or activate or increase circulation of one or more immune cells (such as natural killer cells and / or cytotoxic T-cells), for the treatment of cancer. The implanted medical device includes two or more electrodes configured to electrically stimulate the splenic nerve, and may further include an ultrasonic transducer configured to receive ultrasonic waves and convert energy from the ultrasonic waves into an electrical energy that powers the device.
Owner:IOTA BIOSCIENCES INC

Chimeric antigen receptors targeting B-cell maturation antigen

The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Engineered immune cells and uses thereof

PCT designated stage expiredWO2024251290A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorsPeptide expression
Provided are engineered natural killer T (NKT) cells expressing chimeric antigen receptors (CARs) targeting CD70, where endogenous expression of CD70is reduced or eliminated. These CAR-NKT cells can proliferate in vivo and persist for a long time, exerting significant tumor-suppressive effects. Provided herein are also IL-15 peptides with improved bioavailability, engineered immune cells expressing such IL-15peptides. Methods for manufacturing the engineered CD70targeting NKT or IL-15 expressing immune cells, as well as the uses of such cells in, for example, cancer treatment, are also provided herein.
Owner:CURE GENETICS CO LTD

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and / or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.
Owner:NKARTA INC

Combined medicine for preventing and / or treating prostatic cancer, application of combined medicine and pharmaceutical composition

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

Compositions and methods for immune cell modulation in adoptive immunotherapies

Compounds that either produced a higher proportion or greater absolute number of phenotypically identified naïve, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
Owner:FATE THERAPEUTICS INC

Interleukin-2 variants and methods of uses thereof

The present invention relates to polypeptides which share primary sequence with human Interleukin 2 (IL-2), except for several amino acids that have been mutated. One panel of IL-2 variants comprise mutations with impressive manufacturability that preferentially promotes the proliferation, survival, activation and / or function of immunosuppressive regulatory T cells (Tregs) (Treg: CD4+CD25+FoxP3+) over effector T cells and Natural Killer Cells (NK). cells. Also includes therapeutic uses of such IL-2 selective agent, used alone, or in combination with immune modulating agents or disease-tissue targeting antibody, protein or peptide to treat Treg cell-deficiency, various autoimmune and inflammatory disorders, organ transplantation and graft-versus-host disease. In another aspect the present invention relates to pharmaceutical compositions comprising the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their selective modulating effect of the immune system on diseases like autoimmune and inflammatory disorders.
Owner:CUGENE INC

Natural killer cells for chordoma therapy

Provided herein are methods and compositions for treating chordoma by preferentially targeting cancer stem cells than non-cancer stem cells in chordoma to effectively treat chordoma. In some embodiments, the chordoma tumors cells (preferentially the cancer stem cells in chordoma) are targeted by modified NK-92 cells (i.e., haNK® cells) that express CARs that comprise means for binding to the PD-L1 and another tumor-specific antigen (e.g., EGFR). In some embodiments, the chordoma tumor cells are targeted by using NK cells in combination with a means for binding to means for binding to the PD-L1 and / or a means for binding another tumor antigen (e.g., EGFR). Each of the treatment methods disclosed above may be implemented prior to, and / or concurrent with radio- and / or chemotherapy, and / or may be employed with immune therapy as is discussed in more detail below.
Owner:IMMUNITYBIO INC

Dual-targeting chimeric antigen receptor, recombinant expression vector, anti-tumor natural killer cell and application

The invention relates to the technical field of tumor immunotherapy, in particular to a dual-targeting chimeric antigen receptor, a recombinant expression vector, an anti-tumor natural killer cell and application, and provides a PD1-DAP10-41BB-P2A-NKG2D-Ig4-CD28-41BB-CD3 zeta fusion receptor.The dual-targeting chimeric antigen receptor can target PD-L1 on the surface of a tumor cell, can also recognize NKG2DLs and can be used for preparing anti-tumor natural killer cells. The broad spectrum of the NK cells is greatly improved, and meanwhile, the immune escape of tumor cells is also reduced.
Owner:XINXIANG MEDICAL UNIV

Fusion protein comprising IL-2 protein and CD80 protein, and use thereof

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.
Owner:GI INNOVATION INC

Method of treating alzheimer's disease with expanded natural killer cells

A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Owner:NKMAX CO LTD

Vaccines comprising peripheral blood mononuclear cells loaded with natural killer t cell ligands and antigens

The present invention relates to an immunoprophylactic and therapeutic vaccine comprising a peripheral blood mononuclear cell loaded with a natural killer T cell ligand and an antigen, and more particularly, to an immunotherapeutic vaccine comprising a peripheral blood mononuclear cell loaded with alpha-galactosylceramide, a natural killer T cell ligand and a glycolipid. The compositions of the present invention are readily available because there is no need to isolate specific cells from peripheral blood mononuclear cells. Besides, the immunization of the peripheral blood mononuclear cells loaded with the natural killer T cell ligands and antigens not only induces the obvious-level activation of the natural killer cells and the natural killer T cells and the response of cytotoxic T lymphocytes, but also has a synergistic treatment effect in the aspect of treating malignant tumors. Therefore, the compound can be beneficially used as an anti-cancer immunotherapeutic agent.
Owner:HILLIDE CO LTD

Method of treating parkinson's disease with expanded natural killer cells

Provided herein is a method for treating Parkinson's disease (PD). The method can include identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating PD.
Owner:NKMAX CO LTD

Fusion protein comprising IL-2 protein and CD80 protein, and use thereof

Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.
Owner:GI INNOVATION INC

Method for expansion and maintenance of NK cells for immunotherapy

The present invention discloses a method for expansion of natural killer (NK) cells or CAR-NK cells using peripheral blood mononuclear cells (PBMCs) and culturing the cells in a medium comprising a feeder layer having a population of mesenchymal stem cells (MSCs) with disrupted or deleted MHC class I gene and / or MHC class II gene and a heterologous gene for expressing Interleukin-21 (IL-21), and Interleukin-2 (IL-2). The present disclosure further provides a method and a model for evaluating natural killer (NK) cells or CAR-NK cells using tester line comprising induced Pluripotent stem cells (iPSCs) comprising disrupted or deleted MHC class I gene and / or MHC class II gene and a heterologous gene encoding a tumor antigen.
Owner:NKURE THERAPEUTICS PTE LTD

Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
Owner:NOVARTIS AG +1